The US Food and Drug Administration (FDA) has cleared EOS imaging’s Micro Dose feature for paediatric imaging.
EOS imaging believes that Micro Dose is an important breakthrough for patients with orthopaedic conditions requiring frequent imaging exams for the continuous monitoring of disease progression and treatment. Initial results presented at the 2013 French Society of Radiology Annual Meeting (JFR 2013) and during the 2014 Annual Meeting of the Radiological Society of North America (RSNA 2014), concluded that Micro Dose generates dosage levels equivalent to a week of naturally-occurring background radiation in paediatric patients receiving 2D and 3D follow-up examinations.
A company press release states that EOS’ low dose radiation imaging addresses an important medical need for paediatric patients that remain particularly sensitive to adverse effects associated with excessive exposure to radiation. Most notably, paediatric patients with scoliosis require frequent imaging sessions to monitor treatment progression, which can increase the risk of radiation-induced cancer later in life.
Marie Meynadier, chief executive officer of EOS imaging, said, “The reduction of radiation exposure during orthopaedic imaging exams remains a foremost concern among radiologists, orthopaedic surgeons and patients. The Micro Dose solution is a giant step forward and is in full accordance with the ‘as low as reasonably achievable’ principle. We are pleased that the FDA’s clearance of our Micro Dose feature will now enable young patients to benefit from this technology in the USA.”